212 related articles for article (PubMed ID: 27142771)
1. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.
Shimada M; Sato S; Oishi T; Itamochi H; Kigawa J; Takeshima N; Aoki D; Aoki Y; Nambu Y; Ochiai K
Int J Clin Oncol; 2016 Oct; 21(5):969-974. PubMed ID: 27142771
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer.
Lee YY; Lee JW; Park HS; Song TJ; Kim MK; Choi CH; Kim TJ; Lee JH; Bae DS; Kim BG
Gynecol Oncol; 2010 Oct; 119(1):87-91. PubMed ID: 20580417
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
[TBL] [Abstract][Full Text] [Related]
5. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
7. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gass P; Thiel FC; Häberle L; Ackermann S; Theuser AK; Hummel N; Boehm S; Kimmig R; Reinthaller A; Becker S; Hilpert F; Janni W; Vergote I; Harter P; Emons J; Hein A; Beckmann MW; Fasching PA; Pöschke P;
Gynecol Oncol; 2024 Apr; 183():25-32. PubMed ID: 38490057
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
Rose PG; Sill MW; McMeekin DS; Ahmed A; Salani R; Yamada SD; Wolfson AH; Fusco N; Fracasso PM
Gynecol Oncol; 2012 Apr; 125(1):158-62. PubMed ID: 22198338
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Tiersten AD; Selleck MJ; Hershman DL; Smith D; Resnik EE; Troxel AB; Brafman LB; Shriberg L
Gynecol Oncol; 2004 Feb; 92(2):635-8. PubMed ID: 14766258
[TBL] [Abstract][Full Text] [Related]
11. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
Brave M; Dagher R; Farrell A; Abraham S; Ramchandani R; Gobburu J; Booth B; Jiang X; Sridhara R; Justice R; Pazdur R
Oncology (Williston Park); 2006 Oct; 20(11):1401-4, 1410; discussion 1410-11, 1415-6. PubMed ID: 17112001
[TBL] [Abstract][Full Text] [Related]
12. A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
Yunokawa M; Katsumata N; Yamamoto H; Kodaira M; Yonemori K; Shimizu C; Ando M; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1369-74. PubMed ID: 23558943
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.
Maluf FC; Leiser AL; Aghajanian C; Sabbatini P; Pezzulli S; Chi DS; Wolf JK; Levenback C; Loh E; Spriggs DR
Int J Gynecol Cancer; 2006; 16(3):1165-71. PubMed ID: 16803501
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
15. The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.
Moon JY; Song IC; Ko YB; Lee HJ
Medicine (Baltimore); 2018 Apr; 97(14):e0340. PubMed ID: 29620661
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
[TBL] [Abstract][Full Text] [Related]
17. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
Zighelboim I; Wright JD; Gao F; Case AS; Massad LS; Mutch DG; Powell MA; Thaker PH; Eisenhauer EL; Cohn DE; Valea FA; Alvarez Secord A; Lippmann LT; Dehdashti F; Rader JS
Gynecol Oncol; 2013 Jul; 130(1):64-8. PubMed ID: 23591400
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant chemotherapy with cisplatin and CPT-11 for advanced cervical cancer].
Nishio S; Kumagai S; Hirai N; Tomioka Y; Oota S; Fujiyoshi K; Hasuo Y; Sugiyama T; Nishida T; Kamura T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):429-35. PubMed ID: 10740637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
